Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - meningococcal polysaccharide group w135, quantity: 10 microgram; meningococcal polysaccharide group c, quantity: 10 microgram; meningococcal polysaccharide group a, quantity: 10 microgram; meningococcal polysaccharide group y, quantity: 10 microgram - injection, solution - excipient ingredients: sodium acetate; tetanus toxoid; sodium chloride; water for injections - menquadfi is indicated for active immunisation for the prevention of invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w and y.,the use of menquadfi should be in accordance with official recommendations.

Singapore - inglese - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - diphtheria toxoid protein; meningococcal (serogroup a) polysaccharide (monovalent conjugate); meningococcal (serogroup c) polysaccharide (monovalent conjugate); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate); meningococcal (serogroup y) polysaccharide (monovalent conjugate) - injection, solution - 48 microgram (diptheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio) - diphtheria toxoid protein 48 mcg/dose (0.5 ml) (diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio); meningococcal (serogroup a) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup c) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup w-135) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml); meningococcal (serogroup y) polysaccharide (monovalent conjugate) 4 mcg/dose (0.5 ml)

Canada - inglese - Health Canada

pfizer canada ulc - meningococcal polysaccharide vaccine grp c; tetanus toxoid - suspension - 10mcg; 20mcg - meningococcal polysaccharide vaccine grp c 10mcg; tetanus toxoid 20mcg - vaccines

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

Canada - inglese - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - powder for solution - 500mcg; 500mcg; 500mcg; 500mcg - meningococcal polysaccharide antigen group a 500mcg; meningococcal polysaccharide antigen group c 500mcg; meningococcal polysaccharide antigen group y 500mcg; meningococcal polysaccharide antigen group w-135 500mcg - vaccines

Canada - inglese - Health Canada

sanofi pasteur limited - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group y; meningococcal polysaccharide antigen group w-135 - kit - 50mcg; 50mcg; 50mcg; 50mcg - meningococcal polysaccharide antigen group a 50mcg; meningococcal polysaccharide antigen group c 50mcg; meningococcal polysaccharide antigen group y 50mcg; meningococcal polysaccharide antigen group w-135 50mcg - vaccines

Canada - inglese - Health Canada

pfizer canada ulc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group w-135; meningococcal polysaccharide antigen group y; tetanus toxoid - kit - 5mcg; 5mcg; 5mcg; 5mcg; 44mcg - meningococcal polysaccharide antigen group a 5mcg; meningococcal polysaccharide antigen group c 5mcg; meningococcal polysaccharide antigen group w-135 5mcg; meningococcal polysaccharide antigen group y 5mcg; tetanus toxoid 44mcg - vaccines

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - neisseria meningitidis c tetanus toxoid - suspension for injection

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) - solution for injection - 4 µg each/0.5 ml - active: meningococcal polysaccharide 48ug (4 µg of each of groups a, c, y & w-135, each separately conjugated to diphtheria toxoid, 48 µg total) excipient: dibasic sodium phosphate monobasic sodium phosphate sodium chloride water for injection - menactra vaccine is indicated for active immunisation in individuals from 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n. meningitidis serogroups a, c, y and w-135. menactra vaccine is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b. menactra vaccine is not indicated for treatment of meningococcal infections. menactra vaccine is not indicated for immunisation against diphtheria.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diphtheria toxoid, quantity: 48 microgram; meningococcal polysaccharide group y, quantity: 4 microgram; meningococcal polysaccharide group w135, quantity: 4 microgram; meningococcal polysaccharide group c, quantity: 4 microgram; meningococcal polysaccharide group a, quantity: 4 microgram - injection, solution - excipient ingredients: monobasic sodium phosphate; sodium chloride; dibasic sodium phosphate - menactra is indicated for active immunisation of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.,menactra is not indicated for the prevention of meningitis caused by other microorganisms or for the prevention of invasive meningococcal disease caused by n meningitidis serogroup b.,menactra is not indicated for treatment of meningococcal infections.,menactra is not indicated for immunisation against diphtheria.